Targeted treatment and new agents in diffuse large B cell lymphoma

International Journal of Hematology

Volumn 92, Issue 1, 2010, Pages 12-24

  Dupire, Sophie ^a   Coiffier, Bertrand ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

DLBCL; Monoclonal antibodies; Targeted therapy

Indexed keywords

AEG 35156; AME 133V; ANGIOGENESIS INHIBITOR; BL 22; BLINATUMOMAB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DT 2219ARL; EPRATUZUMAB; FLAVOPIRIDOL; GA 101; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INOTUZUMAB OZOGAMICIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDI 551; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD19; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD22; MONOCLONAL ANTIBODY CD40; MONOCLONAL ANTIBODY CD74; OCRELIZUMAB; OFATUMUMAB; PIXANTRONE; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; SAR 3419; SGN 30; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; VINCRISTINE;

B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; HUMAN; LARGE CELL LYMPHOMA; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; TREATMENT OUTCOME;

EID: 77955174212     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0609-6     Document Type: Review

References (98)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.
2. LM El-Helw BW Hancock 2009 Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas Future Oncol 5 445 453 10.2217/fon.09.13 1:CAS:528:DC%2BD1MXmtF2qu70%3D 19450173
3. P Borchmann F Morschhauser A Parry, et al. 2003 Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas Haematologica 88 888 894 1:CAS:528:DC%2BD3sXovVGhsL8%3D 12935976
4. ST Lim L Fayad A Tulpule, et al. 2007 A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma Leuk Lymphoma 48 374 380 10.1080/10428190601060496 1:CAS:528:DC%2BD2sXjsVKnu7w%3D 17325899
5. Pettengell R, Narayanan G, Mendoza F, et al. Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2009;27.
6. Herbrecht R, Couban S, Weissinger F, Gorbatchevsky I, Van der Jagt RH. CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) compared to CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, rituxamib) in first-line therapy of diffuse large B cell lymphoma (DLBCL): an interim analysis. Blood. 2007;110.
7. BD Cheson MJ Rummel 2009 Bendamustine: rebirth of an old drug J Clin Oncol 27 1492 1501 10.1200/JCO.2008.18.7252 1:CAS:528:DC%2BD1MXksF2hsL8%3D 19224851
8. E Weidmann SZ Kim A Rost, et al. 2002 Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma Ann Oncol 13 1285 1289 10.1093/annonc/mdf189 1:STN:280:DC%2BD38visVequw%3D%3D 12181253
9. S Fulda 2009 Inhibitor of apoptosis proteins in hematological malignancies Leukemia 23 467 476 10.1038/leu.2008.329 1:CAS:528: DC%2BD1MXivVKhu7o%3D 19039324
10. JC Reed 2008 Bcl-2-family proteins and hematologic malignancies: history and future prospects Blood 111 3322 3330 10.1182/blood-2007-09-078162 1:CAS:528:DC%2BD1cXktlWnu7k%3D 18362212
11. B Pro B Leber M Smith, et al. 2008 Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma Br J Haematol 143 355 360 10.1111/j.1365-2141.2008.07353.x 1:CAS:528:DC%2BD1cXhsVeqsLvO 18764869
12. Y Sun J Wu A Aboukameel, et al. 2008 Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo Cancer Biol Ther 7 1418 1426 1:CAS:528:DC%2BD1cXhsVKms73N 18769131
13. L Paoluzzi M Gonen JR Gardner, et al. 2008 Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma Blood 111 5350 5358 10.1182/blood-2007-12-129833 1:CAS:528:DC%2BD1cXntFWns7w%3D 18292288
14. MH Kang CP Reynolds 2009 Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin Cancer Res 15 1126 1132 10.1158/1078-0432.CCR-08-0144 1:CAS:528:DC%2BD1MXitVOksLg%3D 19228717
15. C Tse AR Shoemaker J Adickes, et al. 2008 ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res 68 3421 3428 10.1158/0008-5472. CAN-07-5836 1:CAS:528:DC%2BD1cXltlSltrs%3D 18451170
16. E Dean D Jodrell K Connolly, et al. 2009 Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer J Clin Oncol 27 1660 1666 10.1200/JCO.2008.19. 5677 1:CAS:528:DC%2BD1MXltVOht7o%3D 19237630
17. AW Tolcher A Mita LD Lewis, et al. 2008 Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin J Clin Oncol 26 5198 5203 10.1200/JCO.2008.17.2064 1:CAS:528:DC%2BD1cXhsVyqsrbN 18824702
18. Cheson B, Vose J, Bartlett N, et al. Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2009;27.
19. A Goy A Younes P McLaughlin, et al. 2005 Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 23 667 675 10.1200/JCO.2005.03.108 1:CAS:528:DC%2BD2MXitVKisL0%3D 15613697
20. V Ribrag C Gisselbrecht C Haioun, et al. 2009 Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA) Cancer 115 4540 4546 10.1002/cncr.24518 1:CAS:528:DC%2BD1MXht1Kit7fN 19593797
21. K Dunleavy S Pittaluga MS Czuczman, et al. 2009 Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood 113 6069 6076 10.1182/blood-2009-01-199679 1:CAS:528: DC%2BD1MXnslSmurs%3D 19380866
22. OA O'Connor AK Stewart M Vallone, et al. 2009 A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies Clin Cancer Res 15 7085 7091 10.1158/1078-0432.CCR-09-0822 19903785
23. PH Wiernik IS Lossos JM Tuscano, et al. 2008 Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma J Clin Oncol 26 4952 4957 10.1200/JCO.2007.15.3429 18606983
24. Czuczman M, Vose J, Zinzani P, et al. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: results from an international study (NHL-003). J Clin Oncol. 2009;27.
25. PA Marks WS Xu 2009 Histone deacetylase inhibitors: potential in cancer therapy J Cell Biochem 107 600 608 10.1002/jcb.22185 1:CAS:528: DC%2BD1MXosFOiurg%3D 19459166
26. EA Olsen YH Kim TM Kuzel, et al. 2007 Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J Clin Oncol 25 3109 3115 10.1200/JCO.2006.10.2434 1:CAS:528:DC%2BD2sXptlGrtrs%3D 17577020
27. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19(5):964-9.
28. Crump M, Andreadis C, Assouline S, et al. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. J Clin Oncol. 2009;26.
29. RL Piekarz R Frye M Turner, et al. 2009 Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J Clin Oncol 27 5410 5417 10.1200/JCO.2008.21.6150 1:CAS:528:DC%2BD1MXhsFKkt7vO 19826128
30. DT Teachey SA Grupp VI Brown 2009 Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies Br J Haematol 145 569 580 10.1111/j.1365-2141.2009. 07657.x 1:CAS:528:DC%2BD1MXmvFyjtbY%3D 19344392
31. G Hess R Herbrecht J Romaguera, et al. 2009 Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 3822 3829 10.1200/JCO.2008.20.7977 1:CAS:528:DC%2BD1MXhtFaitrrN 19581539
32. Reeder C, Gornet M, Habermann T, et al. A Phase II Trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL). Blood. 2007;110.
33. M Mita K Sankhala I Abdel-Karim A Mita F Giles 2008 Deforolimus (AP23573) a novel mTOR inhibitor in clinical development Expert Opin Investig Drugs 17 1947 1954 10.1517/13543780802556485 1:CAS:528:DC%2BD1cXhtlyjtrrN 19012509
34. JR Valbuena GZ Rassidakis P Lin, et al. 2005 Expression of heat-shock protein-90 in non-Hodgkin's lymphomas Mod Pathol 18 1343 1349 10.1038/modpathol.3800459 1:CAS:528:DC%2BD2MXhtVWiu7fJ 16056252
35. EG Mimnaugh W Xu M Vos, et al. 2004 Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity Mol Cancer Ther 3 551 566 1:CAS:528:DC%2BD2cXjvVKntb8%3D 15141013
36. MA Shipp KN Ross P Tamayo, et al. 2002 Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med 8 68 74 10.1038/nm0102-68 1:CAS:528:DC%2BD38XjtlygsQ%3D%3D 11786909
37. S Li M Phong M Lahn, et al. 2007 Retrospective analysis of protein kinase C-beta (PKC-β) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas Biol Direct 2 8 10.1186/1745-6150-2-8 17313671
38. JR Graff AM McNulty KR Hanna, et al. 2005 The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts Cancer Res 65 7462 7469 10.1158/0008-5472. CAN-05-0071 1:CAS:528:DC%2BD2MXns1Wqsrc%3D 16103100
39. MJ Robertson BS Kahl JM Vose, et al. 2007 Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma J Clin Oncol 25 1741 1746 10.1200/JCO.2006.09.3146 1:CAS:528:DC%2BD2sXlvFyktbg%3D 17389337
40. RL Hornung JW Pearson M Beckwith DL Longo 1992 Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity Cancer Res 52 101 107 1:CAS:528: DyaK38XltFSrsQ%3D%3D 1727368
41. MC Bosco S Rottschafer LS Taylor JR Ortaldo DL Longo I Espinoza-Delgado 1997 The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression Blood 89 3402 3411 1:CAS:528: DyaK2sXivVyktrg%3D 9129048
42. A Dowlati HM Lazarus P Hartman, et al. 2003 Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies Clin Cancer Res 9 5929 5935 1:CAS:528:DC%2BD3sXpsl2ls7o%3D 14676117
43. PM Barr HM Lazarus BW Cooper, et al. 2009 Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant Am J Hematol 84 484 487 10.1002/ajh.21449 1:CAS:528:DC%2BD1MXhtVGisLjE 19536846
44. ML Varterasian RM Mohammad DS Eilender, et al. 1998 Phase I study of Bryostatin 1 in patients with relapsed non-Hodgkins lymphoma and chronic lymphocytic leukemia J Clin Oncol 16 56 62 1:CAS:528:DyaK1cXmtleqsw%3D%3D 9440723
45. NT Ihle G Powis 2009 Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy Mol Cancer Ther 8 1 9 10.1158/1535-7163.MCT-08-0801 1:CAS:528:DC%2BD1MXjvFSntA%3D%3D 19139107
46. L Zhao PK Vogt 2008 Class I PI3K in oncogenic cellular transformation Oncogene 27 5486 5496 10.1038/onc.2008.244 1:CAS:528:DC%2BD1cXhtFWiur%2FP 18794883
47. Flinn I, Byrd J, Furman R, et al. Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110{Delta} isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-cell malignancies. Blood. 2009;114.
48. D Gratzinger S Zhao RJ Tibshirani, et al. 2008 Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy Lab Invest 88 38 47 10.1038/labinvest.3700697 1:CAS:528:DC%2BD1cXhtVyhug%3D%3D 17998899
49. C Igreja M Courinha AS Cachaco, et al. 2007 Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients Haematologica 92 469 477 10.3324/haematol.10723 17488657
50. AT Stopeck JM Unger LM Rimsza, et al. 2009 A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group study S0108 Leuk Lymphoma 50 728 735 10.1080/10428190902856808 1:CAS:528:DC%2BD1MXmt1SjtL8%3D 19373598
51. KN Ganjoo CS An MJ Robertson, et al. 2006 Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis Leuk Lymphoma 47 998 1005 10.1080/10428190600563821 1:CAS:528:DC%2BD28XpvVGru7o%3D 16840188
52. RE Davis VN Ngo G Lenz, et al. 2010 Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 463 88 92 10.1038/nature08638 1:CAS:528:DC%2BC3cXhvFCitw%3D%3D 20054396
53. T Kurosaki M Hikida 2009 Tyrosine kinases and their substrates in B lymphocytes Immunol Rev 228 132 148 10.1111/j.1600-065X.2008.00748.x 1:CAS:528:DC%2BD1MXhsFGls7rK 19290925
54. L Chen S Monti P Juszczynski, et al. 2008 SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma Blood 111 2230 2237 10.1182/blood-2007-07-100115 1:CAS:528: DC%2BD1cXisVeit78%3D 18006696
55. S Monti KJ Savage JL Kutok, et al. 2005 Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response Blood 105 1851 1861 10.1182/blood-2004-07-2947 1:CAS:528:DC%2BD2MXitVOnsrY%3D 15550490
56. RM Young IR Hardy RL Clarke, et al. 2009 Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target Blood 113 2508 2516 10.1182/blood-2008-05-158618 1:CAS:528:DC%2BD1MXjsFKhu7c%3D 18981293
57. JW Friedberg J Sharman J Sweetenham, et al. 2010 Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 2578 2585 10.1182/blood-2009-08- 236471 1:CAS:528:DC%2BC3cXksFOhs70%3D 19965662
58. AM Senderowicz D Headlee SF Stinson, et al. 1998 Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms J Clin Oncol 16 2986 2999 1:CAS:528:DyaK1cXmtFSls7Y%3D 9738567
59. Tay K, Shapiro G, Disinski M, et al. Phase I/II study of a hybrid schedule of flavopiridol in relapsed/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2009;27.
60. BA Christian MR Grever JC Byrd TS Lin 2009 Flavopiridol in chronic lymphocytic leukemia: a concise review Clin Lymphoma Myeloma 9 Suppl 3 S179 S185 10.3816/CLM.2009.s.009 1:CAS:528:DC%2BD1MXhtlantLbN 19778838
61. DS Hong SM Sebti RA Newman, et al. 2009 Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies Clin Cancer Res 15 7061 7068 10.1158/1078-0432.CCR-09-1241 1:CAS:528:DC%2BD1MXhtl2ktLbF 19903778
62. JL Harousseau 2007 Farnesyltransferase inhibitors in hematologic malignancies Blood Rev 21 173 182 10.1016/j.blre.2006.12.001 1:CAS:528:DC%2BD2sXovFSjurw%3D 17293017
63. Witzig T, Maurer M, Johnston P, et al. Oral Tipifarnib (R115777) has single agent anti-tumor activity in patients with relapsed aggressive non-Hodgkin lymphoma (NHL): results of a phase II trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274). Blood. 2006;108.
64. P McLaughlin AJ Grillo-Lopez BK Link, et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 2825 2833 1:CAS:528:DyaK1cXlsFCgu7c%3D 9704735
65. B Coiffier E Lepage J Briere, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 10.1056/NEJMoa011795 1:CAS:528: DC%2BD38XmslGgsw%3D%3D 11807147
66. B Coiffier 2007 Rituximab therapy in malignant lymphoma Oncogene 26 3603 3613 10.1038/sj.onc.1210376 1:CAS:528:DC%2BD2sXlslCqsbs%3D 17530014
67. P Colombat G Salles N Brousse, et al. 2001 Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation Blood 97 101 106 10.1182/blood.V97.1.101 1:CAS:528:DC%2BD3MXis1Cjsg%3D%3D 11133748
68. Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 monoclonal antibody, in patients with relapsed/refractory follicular lymphoma. Ann Oncol. 2010. doi: 10.1093/annonc/mdq027.
69. JL Teeling RR French MS Cragg, et al. 2004 Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas Blood 104 1793 1800 10.1182/blood-2004-01-0039 1:CAS:528: DC%2BD2cXns1Oktbc%3D 15172969
70. A Hagenbeek O Gadeberg P Johnson, et al. 2008 First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Blood 111 5486 5495 10.1182/blood-2007-10-117671 1:CAS:528:DC%2BD1cXnsVOkt78%3D 18390837
71. DM Goldenberg EA Rossi R Stein, et al. 2009 Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody Blood 113 1062 1070 10.1182/blood-2008-07-168146 1:CAS:528:DC%2BD1MXhvVajsLY%3D 18941114
72. F Morschhauser JP Leonard L Fayad, et al. 2009 Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results J Clin Oncol 27 3346 3353 10.1200/JCO.2008.19.9117 1:CAS:528: DC%2BD1MXpvFejt7g%3D 19451441
73. Salles G, Morschhauser F, Lamy T, et al. Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ non-Hodgkin lymphoma (NHL). Blood. 2009;114.
74. Weiner G, Bowles J, Link B, Campbell M, Wooldridge J, Breitmeyer J. Anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2005;106.
75. J Carnahan R Stein Z Qu, et al. 2007 Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab Mol Immunol 44 1331 1341 10.1016/j.molimm.2006.05.007 1:CAS:528: DC%2BD28XpvVOgtr4%3D 16814387
76. JP Leonard M Coleman JC Ketas, et al. 2004 Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results Clin Cancer Res 10 5327 5334 10.1158/1078-0432.CCR-04-0294 1:CAS:528:DC%2BD2cXmvFSlt78%3D 15328168
77. JP Leonard M Coleman J Ketas, et al. 2005 Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma J Clin Oncol 23 5044 5051 10.1200/JCO.2005.13.821 1:CAS:528:DC%2BD2MXpsFWmtLg%3D 15955901
78. EA Rossi DM Goldenberg TM Cardillo R Stein CH Chang 2009 Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma Blood 113 6161 6171 10.1182/blood-2008-10-187138 1:CAS:528:DC%2BD1MXnslSmu7g%3D 19372261
79. IN Micallef BS Kahl MJ Maurer, et al. 2006 A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma Cancer 107 2826 2832 10.1002/cncr.22342 1:CAS:528: DC%2BD2sXovF2juw%3D%3D 17099879
80. JF DiJoseph ME Goad MM Dougher, et al. 2004 Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma Clin Cancer Res 10 8620 8629 10.1158/1078-0432.CCR-04-1134 1:CAS:528:DC%2BD2cXhtFGjs7fK 15623646
81. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085-93.
82. RJ Kreitman 2009 Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies Curr Pharm Des 15 2652 2664 10.2174/138161209788923949 1:CAS:528:DC%2BD1MXptVajsro%3D 19689336
83. http://clinicaltrials.gov/ct2/show/NCT00983619. Accessed 17 Apr 2010.
84. AM Al-Katib A Aboukameel R Mohammad MC Bissery C Zuany-Amorim 2009 Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma Clin Cancer Res 15 4038 4045 10.1158/1078-0432.CCR-08- 2808 1:CAS:528:DC%2BD1MXntlOis7c%3D 19509168
85. Younes A, Gordon L, Kim S, et al. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Blood. 2009;114.
86. D Dornan F Bennett Y Chen, et al. 2009 Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma Blood 114 2721 2729 1:CAS:528:DC%2BD1MXht1eit7jO 19633198
87. DA Vallera H Chen AR Sicheneder A Panoskaltsis-Mortari EP Taras 2009 Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy Leuk Res 33 1233 1242 10.1016/j.leukres.2009.02.006 1:CAS:528:DC%2BD1MXnvVaktro%3D 19327829
88. D Nagorsen R Bargou D Ruttinger P Kufer PA Baeuerle G Zugmaier 2009 Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab Leuk Lymphoma 50 886 891 10.1080/10428190902943077 1:CAS:528:DC%2BD1MXntFChs7Y%3D 19455460
89. R Advani A Forero-Torres RR Furman, et al. 2009 Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma J Clin Oncol 27 4371 4377 10.1200/JCO.2008.21.3017 1:CAS:528:DC%2BD1MXht1WisbnN 19636010
90. Advani R, De Vos S, Ansell SM, et al. A phase 2 clinical trial of SGN-40 monotherapy in relapsed diffuse large B-cell lymphoma. Blood. 2008;112.
91. http://clinicaltrials.gov/ct2/show/NCT00670592. Accessed 17 Apr 2010.
92. NL Bartlett A Younes MH Carabasi, et al. 2008 A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies Blood 111 1848 1854 10.1182/blood-2007-07-099317 1:CAS:528:DC%2BD1cXisVeisrg%3D 18079362
93. Chen X, Chang C, Goldenberg D. Efficient binding, but moderate modulation, of human dendritic cell functions by milatuzumab, a humanized anti-CD74 monoclonal antibody. Blood. 2008;112.
94. Kaufman J, Niesvizky R, Stadtmauer E, et al. First trial of humanized anti-CD74 monoclonal antibody (MAb), milatuzumab, in multiple myeloma. Blood. 2008;112.
95. J Rech R Repp D Rech, et al. 2006 A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study Leuk Lymphoma 47 2147 2154 10.1080/10428190600757944 1:CAS:528:DC%2BD28XhtlCiu7%2FM 17071489
96. MR Smith F Jin I Joshi 2007 Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2 Clin Cancer Res 13 5528s 5534s 10.1158/1078-0432.CCR-07-0982 1:CAS:528:DC%2BD2sXhtVCitL3F 17875785
97. SJ Goldsmith 2010 Radioimmunotherapy of lymphoma: bexxar and zevalin Semin Nucl Med 40 122 135 10.1053/j.semnuclmed.2009.11.002 20113680
98. F Morschhauser T Illidge D Huglo, et al. 2007 Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation Blood 110 54 58 10.1182/blood-2007-01-068056 1:CAS:528:DC%2BD2sXnsVais78%3D 17387223